Search

Displaying results 6991 - 7000 of 8696 in total
  1. Drug

    AAV-RPE65

    go.drugbank.com/drugs/DB18343
    Experimental

    AAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene

  2. Drug

    WU-NK-101

    go.drugbank.com/drugs/DB18350
    Investigational

    WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product

  3. Drug

    Danofloxacin

    go.drugbank.com/drugs/DB11393
    ExperimentalVet approved

    Danofloxacin is an antibiotic agent from the family of the fluoroquinolones used in veterinary medicine.

  4. Drug

    Nemtabrutinib

    go.drugbank.com/drugs/DB18866
    Investigational

    Nemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic

  5. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients).

  6. Drug

    RD06-04

    go.drugbank.com/drugs/DB24647
    Investigational

    RD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).

  7. Drug

    Amniotic membrane

    go.drugbank.com/drugs/DB33970
    Experimental

    Amniotic membrane is under investigation in clinical trial NCT07824596 (The Role of Amniotic Membrane in Promoting Rapid Recovery of Buccal Mucosal Defect After Harvesting Oral Mucosa for Urethral Reconstruction

  8. Drug

    Basic Fibroblast Growth Factor

    go.drugbank.com/drugs/DB14131
    Investigational

    Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials. … The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages.

  9. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. … The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.

  10. Drug

    Furazidin

    go.drugbank.com/drugs/DB13475
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use